Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years
JAMA Dermatology · 01.01.2025 · 161 (1) · 56
DOI: 10.1001/jamadermatol.2024.4688 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JAMA Dermatology, erschienen am 01.01.2025. Verfasst von April W Armstrong und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of Dermatology, University of California Los Angeles David Geffen School of Medicine, Los Angeles. Hauptthemen laut MEDLINE: Psoriasis. Die Arbeit wurde bisher 61-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Safe and effective long-term treatments for moderate to severe plaque psoriasis are needed.
Objective
To evaluate the long-term safety and efficacy of deucravacitinib through 3 years (week 148) in the randomized POETYK PSO-1, PSO-2, and nonrandomized long-term extension (LTE) trials. Design, Setting, and Participants PSO-1/PSO-2 were global, 52-week, randomized, double-blinded phase 3 trials in patients with moderate to severe plaque psoriasis. After completing 52 weeks of treatment in PSO-1/PSO-2, patients could enroll in the prespecified, ongoing, nonrandomized LTE trial. The peak of the global COVID-19 pandemic coincided with the LTE trial. Patient enrollment in the LTE started August 12, 2019; safety and efficacy were assessed through June 15, 2022; and these data were analyzed through June 28, 2024.
Interventions
The PSO-1/PSO-2 trials randomized patients 1:2:1 to oral placebo, deucravacitinib, 6 mg once daily, or apremilast, 30 mg twice daily. Patients enrolling in the LTE trial received open-label deucravacitinib, 6 mg once daily. Main Outcomes And Measures Safety outcomes were evaluated in patients who received 1 or more doses of deucravacitinib. Efficacy outcomes included 75% or greater or 90% or greater reduction from baseline in Psoriasis Area and Severity Index (PASI 75/90) and static Physician Global Assessment scores of 0 (clear) or 1 (almost clear) (sPGA 0/1) and were assessed in patients who received deucravacitinib treatment from day 1 of the parent trials who continued in the LTE trial.
Results
Of 1519 patients who received 1 or more doses of deucravacitinib, 513 received continuous deucravacitinib treatment from day 1 and entered the LTE trial. Exposure-adjusted incidence rates (EAIRs) per 100 person-years were decreased or similar in the 1-year vs 3-year cumulative periods, respectively, for adverse events (AEs) (229.2 vs 144.8; 95% CI, 215.4-243.9 vs 137.1-153.0), serious AEs (5.7 vs 5.5; 95% CI, 4.4-7.4 vs 4.7-6.4), discontinuations due to AEs (4.4 vs 2.4; 95% CI, 3.3-5.9 vs 2.0-3.0), and deaths (0.2 vs 0.3; 95% CI, 0.1-0.8 vs 0.2-0.6). Incidence rates of the most common AEs (EAIR per 100 person-years ≥5) during the 1-year and 3-year cumulative periods, respectively, were nasopharyngitis (26.1 vs 11.4; 95% CI, 23.0-29.8 vs 10.2-12.7), COVID-19 (0.5 vs 8.0; 95% CI, 0.2-1.2 vs 7.1-9.1), and upper respiratory tract infection (13.4 vs 6.2; 95% CI, 11.3-16.0 vs 5.4-7.2). EAIRs for AEs of interest, including herpes zoster, major adverse cardiovascular events, and malignant diseases, remained low and were decreased or comparable between the 1-year and 3-year cumulative periods. Clinical response rates were maintained through 3 years. Conclusions and Relevance The findings of this integrated analysis of the phase 3 POETYK PSO-1, PSO-2, and nonrandomized LTE trials demonstrate a consistent safety profile and durable clinical response of continuous treatment with deucravacitinib through 3 years of treatment in patients with psoriasis. Trial Registration ClinicalTrials.gov Identifiers: NCT03624127 , NCT03611751 , and NCT04036435 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Dermatology, University of California Los Angeles David Geffen School of Medicine, Los Angeles.
- Kimberly and Eric J. Waldman Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.
- Dermatology Centre, Northern Care Alliance NHS Foundation Trust, Manchester, United Kingdom.
- NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom.
- Dermatology Research Associates, Los Angeles, California.
- Faculty of Medicine, Fukuoka University Hospital, Fukuoka, Japan.
Zitieren
APA
Armstrong, A. W., Lebwohl, M., Warren, R. B., Sofen, H., Imafuku, S., Ohtsuki, M., Spelman, L., Passeron, T., Papp, K. A., Kisa, R. M., Vaile, J., Berger, V., Vritzali, E., Hoyt, K., Colombo, M. J., Scotto, J., Banerjee, S., Strober, B., Thaçi, D., & Blauvelt, A. (2025). Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years. JAMA Dermatology, 161(1), 56. https://doi.org/10.1001/jamadermatol.2024.4688
Vancouver
Armstrong AW, Lebwohl M, Warren RB, Sofen H, Imafuku S, Ohtsuki M, et al. Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years. JAMA Dermatology. 2025;161(1):56. doi:10.1001/jamadermatol.2024.4688
BibTeX
@article{Armstrong2025,
author = {Armstrong, April W and Lebwohl, Mark and Warren, Richard B and Sofen, Howard and Imafuku, Shinichi and Ohtsuki, Mamitaro and Spelman, Lynda and Passeron, Thierry and Papp, Kim A and Kisa, Renata M and Vaile, John and Berger, Victoria and Vritzali, Eleni and Hoyt, Kim and Colombo, Matthew J and Scotto, Julie and Banerjee, Subhashis and Strober, Bruce and Thaçi, Diamant and Blauvelt, Andrew},
title = {Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years},
journal = {JAMA Dermatology},
year = {2025},
volume = {161},
number = {1},
pages = {56},
doi = {10.1001/jamadermatol.2024.4688}
}
EUVIMED